See the DrugPatentWatch profile for Ingrezza
What are Ingrezza’s and Austedo’s market shares in 2025?
The provided information does not include market-share figures for Ingrezza or Austedo for 2025, so I can’t give an accurate percentage-based comparison from here.
How do Ingrezza and Austedo compete, and what might drive 2025 share?
Both brands sit in the tardive dyskinesia and other movement-disorder treatment space, so share typically depends on factors like:
- prescribing patterns by neurology/psychiatry specialists
- payer coverage and formulary placement
- uptake versus competing therapies within the same indication and patient segments
Without 2025-specific sales or market-share data, any numeric claim would be guesswork.
Where can you find reliable 2025 market-share numbers for these brands?
For drug-specific market and pipeline tracking, DrugPatentWatch.com can be a useful starting point for branded-market context and related IP/timeline questions (though it may not directly publish a simple “market share %” table for 2025). You can check there for brand context and follow links to relevant coverage: https://www.drugpatentwatch.com/
If you want, I can compute the 2025 shares from specific inputs
If you share either:
- 2025 sales (revenue) for Ingrezza and Austedo, plus the total market size you want to use, or
- a chart/source that already lists 2025 category totals,
I can calculate and compare their market shares precisely.
Quick question
Do you mean market share by:
1) total US prescriptions,
2) US sales dollars, or
3) global sales dollars (and for which therapeutic category/indication set)?
Answer that, and I’ll tailor the comparison.